DPPC, cholesterol and stearylamine
|
CAT or SOD
|
Reverse-phase evaporation
|
–
|
Intravenous
|
Decrease lipid peroxidation products (malondialdehyde, conjugated dienes, lipid hydroperoxides)
|
[93]
|
DPPC
|
a-Tocopherol
|
Reverse-phase evaporation
|
320 ± 40 nm
|
Intratracheal
|
Reduce myeloperoxidase activity and reverse of phorbol myristate acetate-induced changes in lung edema, lipid peroxidation, enzyme and alkaline phosphatase activities
|
[94]
|
DPPC and cholesterol
|
Cu, Zn SOD and CAT
|
Reverse-phase evaporation
|
200 nm
|
Intratracheal, instillation
|
Increase antioxidant activity of alveolar type II cell, increase lung antioxidant enzyme levels
|
[95, 96]
|
DPPC
|
SOD and/or CAT
|
Reverse-phase evaporation
|
0.1–0.4 μm
|
Intratracheal
|
Prevent the chronic vascular and parenchymal damage due to oxygen toxicity
|
[97]
|
DPPC
|
NAC
|
Reverse-phase evaporation
|
-
|
Intratracheal
|
Increase pulmonary glutathione
|
[98]
|
DPPC
|
NAC, glutathione, a-tocopherol
|
Thin-film hydration method
|
100 nm
|
Intratracheal instillation
|
Reduce CINC-1, IL-1β, and TNF-α
|
[99]
|
Phospholipid and cholesterol
|
NAC
|
Reverse phase evaporation and spray drying
| ∼100 nm |
Inhalation
|
Against TBARS production
|
[100]
|
DPPC
|
a-Tocopherol
|
Solvent evaporation method
|
-
|
Intraperitoneal, injection
|
Reduce acute inflammatory, cell influx and suppress collagen formation in lung tissue
|
[101]
|
Chitosan, hyaluronan, and phospholipids
|
Curcumin
|
Sonication, stirring
|
130 nm
|
A549 cells
|
Cell relative metabolic activity ≥ 80% after treated with hydrogen peroxide
|
[102]
|